<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TETRACYCLINE HYDROCHLORIDE - tetracycline hydrochloride capsule </strong><br>Blenheim Pharmacal, Inc.<br></p></div>
<h1>TETRACYCLINE HYDROCHLORIDE CAPSULES USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8183c3e-1ca7-43a8-bd3e-658b596ceb62"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">For Oral Use</span></p>
<p><span class="Bold">Rx only</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_347eef17-f55f-49e1-99f7-e0a9bcb2dcc6"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Tetracycline is a yellow, odorless, crystalline powder. Tetracycline is stable in air but exposure to strong sunlight causes it to darken. Its potency is affected in solutions of pH below 2 and is rapidly destroyed by alkali hydroxide solutions. Tetracycline is very slightly soluble in water, freely soluble in dilute acid and in alkali hydroxide solutions, sparingly soluble in alcohol, and practically insoluble in chloroform and in ether. The chemical name for tetracycline hydrochloride is 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,-12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecar-boxamide monohydrochloride. Its structural formula is as follows:</p>
<div class="Figure"><img alt="Tetracycline structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d07410b3-37e6-4382-97de-0c2676bc1103&amp;name=8712d942-19e4-4bf4-8d87-076b3f8c743c-01.jpg"></div>
<p>C<span class="Sub">22</span>H<span class="Sub">24</span>N<span class="Sub">2</span>0<span class="Sub">8</span>•HCI M.W. 480.90</p>
<p>Each capsule, for oral administration, contains 250 mg or 500 mg tetracycline hydrochloride. In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, pregelatinized starch and stearic acid. The inactive ingredients for the gelatin capsules include: (250 mg) FD&amp;C Yellow No. 6, D&amp;C Yellow No. 10, and titanium dioxide; (500 mg): FD&amp;C Blue No. 1, FD&amp;C Red No. 40, D&amp;C Yellow No. 10, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a6e4904a-f362-4f8c-a6b6-c8bb781dbf67"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cf4a3f21-d98c-49cd-aee3-2f98ab4ea344"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Tetracyclines are primarily bacteriostatic and exert their antimicrobial effect by the inhibition of protein synthesis. Tetracycline is active against a wide range of gram-negative and gram-positive organisms. The drugs in the tetracycline class have closely similar antimicrobial spectra, and cross-resistance among them is common. While <span class="Italics">in vitro</span> studies have demonstrated the susceptibility of most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, clinical efficacy for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> other than those included in the <span class="Bold">INDICATIONS AND USAGE </span>section has not been documented.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1cde6152-af46-42fa-9d51-315586c7c8d3"></a><a name="section-3.1.1"></a><p></p>
<h3>Gram-negative Bacteria</h3>
<p class="First"><span class="Italics">Neisseria <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span></span></p>
<p><span class="Italics">Haemophilus ducreyi</span></p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p><span class="Italics">Yersinia pestis (formerly Pasteurella pestis)</span></p>
<p><span class="Italics">Francisella tularensis (formerly Pasteurella tularensis)</span></p>
<p><span class="Italics">Vibrio <span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">cholera</span> (formerly Vibrio comma)</span></p>
<p><span class="Italics">Bartonella bacilliformis</span></p>
<p><span class="Italics">Brucella species</span></p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of gram-negative microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended:</p>
<p><span class="Italics">Escherichia coli</span></p>
<p><span class="Italics">Klebsiella species</span></p>
<p><span class="Italics">Enterobacter aerogenes</span></p>
<p><span class="Italics">Shigella species</span></p>
<p><span class="Italics">Acinetobacter species (formerly Mima species and Herellea species)</span></p>
<p><span class="Italics">Bacteroides species</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8767241b-88fd-4f37-902b-08d52773295b"></a><a name="section-3.1.2"></a><p></p>
<h3>Gram-positive Bacteria</h3>
<p class="First">Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of gram-positive microorganisms have been shown to be resistant to tetracycline, culture and susceptibility testing are recommended. Up to 44 percent of <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pyogenes</span> and 74 percent of <span class="Italics">Streptococcus faecalis</span> have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organisms have been demonstrated to be susceptible.</p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Enterococcus group (Streptococcus faecalis and Streptococcus faecium)</span></p>
<p><span class="Italics">Alpha-hemolytic Streptococci (viridans group)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49460170-d0dd-4588-87a2-efda1585141e"></a><a name="section-3.1.3"></a><p></p>
<h3>Other microorganisms</h3>
<p class="First"><span class="Italics">Chlamydia psittaci</span></p>
<p><span class="Italics">Chlamydia trachomatis</span></p>
<p><span class="Italics">Ureaplasma urealyticum</span></p>
<p><span class="Italics">Borrelia recurrentis</span></p>
<p><span class="Italics">Treponema pallidum</span></p>
<p><span class="Italics">Treponema pertenue</span></p>
<p><span class="Italics">Clostridia species</span></p>
<p><span class="Italics">Fusobacterium fusiforme</span></p>
<p><span class="Italics">Actinomyces species</span></p>
<p><span class="Italics">Bacillus anthraxis</span></p>
<p><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></p>
<p><span class="Italics">Entamoeba species</span></p>
<p><span class="Italics">Balantidium coli</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d786af03-bc41-410b-8145-e99b4000f64e"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Testing</h2>
<p class="First">A tetracycline disk may be used to determine microbial susceptibility to drugs in the tetracycline class. If the Kirby-Bauer method of disk susceptibility testing is used, a 30 mcg tetracycline disk should give a zone of at least 19 mm when tested against a tetracycline susceptible bacterial <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>. Microorganisms may be considered susceptible if the MIC (<span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span>) is not more than 4 mcg/mL and intermediate if the MIC is 4 to 12.5 mcg/mL.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_5efb4e63-4a8d-4dd7-848c-26c861f3b17c"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Tetracycline is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms in the conditions listed below:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span> caused by <span class="Italics">Streptococcus pyogenes</span>, <span class="Italics">Streptococcus pneumoniae</span> and <span class="Italics">Hemophilus influenzae</span>. Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. </li>
<li><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span> caused by <span class="Italics">Streptococcus pyogenes</span>, <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Mycoplasma pneumoniae</span> (Eaton agent, and <span class="Italics">Klebsiella</span> sp.)</li>
<li>Skin and <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span> caused by <span class="Italics">Streptococcus pyogenes</span>, <span class="Italics">Staphylococcus aureaus</span>. (Tetracyclines are not the drugs of choice in the treatment of any type of <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span>.)</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by rickettsia including Rocky Mountain spotted <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, typhus group <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, Q <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, rickettsialpox.</li>
<li>Psittacosis or ornithosis caused by <span class="Italics">Chlamydia Psittaci</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by <span class="Italics">Chlamydia trachomatis</span> such as uncomplicated urethral, endocervical or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, inclusion <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, trachoma, and lymphogranuloma venereum.</li>
<li><span class="product-label-link" type="condition" conceptid="4163983" conceptname="Granuloma">Granuloma</span> inquinale caused by <span class="Italics">Calymmatobacterium granulomatis</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="440637" conceptname="Relapsing fever">Relapsing fever</span> caused by <span class="Italics">Borrelia</span> sp.</li>
<li>Bartonellosis caused by Bartonella <span class="Italics">bacilliformis</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">Chancroid</span> caused by <span class="Italics">Hemophilus ducreyi</span>.</li>
<li>Tularemia caused by <span class="Italics">Francisella tularensis</span>.</li>
<li>Plaque caused by <span class="Italics">Yersinia pestis</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">Cholera</span> caused by <span class="Italics">Vibrio cholerae</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="441497" conceptname="Brucellosis">Brucellosis</span> caused by <span class="Italics">Brucella</span> species (tetracycline may be used in conjunction with an aminoglycoside).</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> due to <span class="Italics">Campylobacter fetus</span>.</li>
<li>As adjunctive therapy in intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> caused by <span class="Italics">Entamoeba histolytica</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella</span>, etc.</li>
<li>Other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible gram-negative organisms such as <span class="Italics">E. coli</span>, <span class="Italics">Enterobacter</span> aerogenes, Shigella sp., Acinetobacter sp., <span class="Italics">Klebsiella</span> sp., and <span class="Italics">Bacteroides</span> sp.</li>
<li>In severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, adjunctive therapy with tetracycline may be useful.</li>
</ul>
<p>When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> and yaws caused by <span class="Italics">Treponema pallidum</span> and <span class="Italics">pertenue</span>, respectively,</li>
<li>Vincent’s <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics">Fusobacterium fusiforme</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Neisseria gonorrhoeae</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> caused by <span class="Italics">Bacillus anthracis</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Listeria monocytogenes</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">actinomycosis</span> caused by <span class="Italics">Actinomyces</span> species,</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Clostridium</span> species.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_c7728360-a172-4454-ad31-a5c399fb537d"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This drug is contraindicated in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the tetracyclines.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_faa61780-aa8e-4e15-901a-7172e42f9759"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW - GRAY - BROWN). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.</p>
<p>All tetracyclines form a stable calcium complex in any bone forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.</p>
<p>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Tetracycline drugs should not be used during pregnancy unless absolutely necessary.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> exists, even usual oral or parenteral doses may lead to excessive systemic accumulation of the drug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated, and, if therapy is prolonged, serum level determinations of the drug may be advisable.</p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs. Treatment should be discontinued at the first evidence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>.</p>
<p>The antianabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, higher serum levels of tetracycline may lead to <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_d218f8a7-b815-4b4b-8491-f1d295a02394"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_1ed77963-e6c9-49ba-80f8-3e779ea56bd0"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">As with other antibiotics, use of this drug may result in overgrowth of nonsusceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, the antibiotic should be discontinued and appropriate therapy should be instituted.</p>
<p>All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to Group A beta-hemolytic streptococci should be treated for at least ten days.</p>
<p>Bulging fontanels in infants and <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> in adults have been reported in individuals receiving tetracyclines. These conditions disappeared when the drug was discontinued.</p>
<p>Incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy, when indicated.</p>
<p>Prescribing tetracycline in the absence of proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cda2e631-2cf6-4589-935a-5290dedb21c2"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including tetracycline should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When tetracycline is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by tetracycline or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_57f5b6f8-386f-476b-9d95-2a2b4407a435"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In venereal diseases, when coexistent <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> is suspected, dark field examinations should be done before treatment is started and the blood serology repeated monthly for at least four months.</p>
<p>In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic studies, should be performed.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_10092a63-69cd-426c-a3b9-31a38c7ab73c"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline in conjunction with penicillin or other bactericidal antibiotics.</p>
<p>Because the tetracyclines have been shown to depress plasma <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</p>
<p>The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.</p>
<p>Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>Concurrent use of tetracycline may render oral contraceptives less effective.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_ac797732-caa5-4bea-b4d1-3c487c5a2c47"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies are currently being conducted to determine whether tetracycline hydrochloride has carcinogenic potential. Some related antibiotics (oxytetracycline, minocycline) have shown evidence of oncogenic activity in rats.</p>
<p>In two <span class="Italics">in vitro</span> mammalian cell assay systems (L 51784y mouse Iymphoma and Chinese hamster lung cells), there was evidence of mutagenicity at tetracycline hydrochloride concentrations of 60 and 10 mcg/mL, respectively.</p>
<p>Tetracycline hydrochloride had no effect on fertility when administered in the diet to male and female rats at a daily intake of 25 times the human dose.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_a98f96e1-8532-49b1-a74f-734478e7a8b6"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_63270772-7f51-4755-bfd4-e4c122dd55f3"></a><a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b921b94a-f030-44ef-ad06-4a95c8a9b4f9"></a><a name="section-7.6.1.1"></a><p></p>
<h4>Pregnancy Category D </h4>
<p class="First">(see <span class="Bold">WARNINGS</span>)</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_3fb15d08-50dc-4d3e-bf59-1617e1effc43"></a><a name="section-7.6.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">(see <span class="Bold">WARNINGS</span>)</p>
<p>Pregnant women with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> may be more prone to develop tetracycline-associated <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_7fa77edb-e6db-45b6-b74f-d095f47e5f4e"></a><a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effect of tetracyclines on labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_e792613c-b64a-4425-b323-76532cbd60fc"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Because of the potential for serious adverse reaction in nursing infants from tetracyclines, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother (see <span class="Bold">WARNINGS</span>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_df7285ec-572e-4c44-bda0-5c62998bfac8"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <span class="Bold">WARNINGS </span>and <span class="Bold">DOSAGE AND ADMINISTRATION.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_15a140ff-ef1e-4ff4-a091-c836dbd4ef2d"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">black hairy tongue</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and inflammatory lesions (with monilial overgrowth) in the anogenital region.</p>
<p>Rare instances of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulceration</span> have been reported in patients receiving particularly the capsule and also the tablet forms of tetracyclines.</p>
<p>Most of the patients were reported to have taken medication immediately before going to bed (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>).</p>
<p><span class="Bold">Teeth: </span>permanent discoloration of teeth may be caused during tooth development. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported (see <span class="Bold">WARNINGS</span>).</p>
<p><span class="Bold">Skin: </span>maculopapular and erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>. <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> has been reported but is uncommon. <span class="product-label-link" type="condition" conceptid="4328079" conceptname="Onycholysis">Onycholysis</span> and discoloration of the nails have been reported rarely. <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> is discussed in <span class="Bold">WARNINGS</span>.</p>
<p><span class="Bold">Renal toxicity: </span>rise in BUN has been reported and is apparently dose related.</p>
<p><span class="Bold">Liver: </span>hepatotoxicity and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> have been observed in patients receiving large doses of tetracycline and in tetracycline-treated patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: </span><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4101602" conceptname="Henoch-Schonlein purpura">anaphylactoid purpura</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reactions, as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>.</p>
<p><span class="Bold">Blood: </span><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported.</p>
<p><span class="Bold">Other: </span>bulging fontanels in infants and intracranial pressure in adults (see <span class="Bold">PRECAUTIONS-General</span>).</p>
<p>When given over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function studies are known to occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_53a0729f-9395-4b54-9ae8-c0e9658a9702"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Tetracycline is not dialyzable.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_1812b66a-09e0-45e4-a01f-8d65b9d6cbdd"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7b6ff6cb-45cf-498b-b349-9e102ac5aebd"></a><a name="section-10.1"></a><p></p>
<h2>Adults</h2>
<p class="First">Usual daily dose, 1 gram as 500 mg b.i.d. or 250 mg q.i.d. Higher doses such as 500 mg q.i.d. may be required for severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or for those <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> which do not respond to the smaller doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_361a9e74-06ee-42f2-9040-1c87b275227d"></a><a name="section-10.2"></a><p></p>
<h2>Children above eight years of age</h2>
<p class="First">Usual daily dose, 10 to 20 mg/lb (25 to 50 mg/kg) body weight divided in four equal doses.</p>
<p>Therapy should be continued for at least 24 to 48 hours after symptoms and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> have subsided.</p>
<p>For treatment of <span class="product-label-link" type="condition" conceptid="441497" conceptname="Brucellosis">brucellosis</span>, 500 mg tetracycline q.i.d. for three weeks should be accompanied by streptomycin, 1 gram intramuscularly twice daily the first week and once daily the second week.</p>
<p>For the treatment of <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> in patients allergic to penicillin, the following dosage of tetracycline is recommended: early <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> (less than one year’s duration)-500 mg q.i.d. for 15 days. <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> of more than one year’s duration (except neurosyphilis)-500 mg q.i.d. for 30 days.</p>
<p>For treatment of <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, the recommended dose is 500 mg by mouth four times a day for seven days.</p>
<p>In cases of moderate to severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> which, in the judgement of the clinician, require long-term treatment, the recommended initial dosage is 1 gram daily in divided doses. When improvement is noted, dosage should be gradually reduced to maintenance levels ranging from 125 mg to 500 mg daily. In some patients it may be possible to maintain adequate remission of lesions with alternate-day or intermittent therapy. Tetracycline therapy of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> should augment the other standard measures known to be of value. Duration of long-term treatment which can safely be recommended has not been established (see <span class="Bold">WARNINGS and Carcinogenicity, Mutagenicity, Impairment of Fertility</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd2c6618-fd63-41eb-8dcb-5f86a65edd6f"></a><a name="section-10.3"></a><p></p>
<h2>Concomitant therapy</h2>
<p class="First">Absorption of tetracycline is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>Food and some dairy products also interfere with absorption.</p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, a therapeutic dose of tetracycline should be administered for at least ten days.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold">WARNINGS</span>): total dosage should be decreased by reduction of recommended individual doses and/or by extending time intervals between doses.</p>
<p>Uncomplicated urethral, endocervical or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults caused by Chlamydia trachomatis: 500 mg, by mouth, four times a day for at least seven days.</p>
<p>Administration of adequate amounts of fluid with the capsule formulation of tetracycline is recommended to wash down the drug and reduce the risk of esophageal irritation and ulceration (see <span class="Bold">ADVERSE REACTIONS</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_99e23978-dd0d-471b-949a-91fb883c9015"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Tetracycline Hydrochloride Capsules USP, 250 mg are available as orange opaque and yellow opaque capsules, imprinted with company logo and 2416, containing 250 mg of tetracycline hydrochloride, packaged in bottles of 100 and 1000 capsules, and unit-dose boxes of 100 capsules.</p>
<p>Tetracycline Hydrochloride Capsules USP, 500 mg are available as black and yellow capsules, imprinted with company logo and 2407, containing 500 mg of tetracycline hydrochloride, packaged in bottles of 100 and 1000 capsules, and unit-dose boxes of 100 capsules.</p>
<p>PHARMACIST: Dispense in a tight, light resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_54f69b30-9898-49be-bf79-dfabcae8f9d0"></a><a name="section-12"></a><p></p>
<h1>ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY</h1>
<p class="First">Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, minocycline, tetracycline PO4 and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO4 and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.</p>
<p>Minocycline, tetracycline PO4, methacycline, doxycycline, tetracycline base, oxytetracycline HCI and tetracycline HCI were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accomplished by high radioactive iodine uptake. Administration of minocycline also produced a large <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> with high radioiodine uptake in rats fed a relatively high iodine diet.</p>
<p>Treatment of various animal species with this class of drugs has also resulted in the induction of <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> in the following: in rats and dogs (minocycline), in chickens (chlortetracycline) and in rats and mice (oxytetracycline). Adrenal gland <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> has been observed in goats and rats treated with oxytetracycline.</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. A 6/2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<p class="First">10544-590-28 Bottle Label<img alt="Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d07410b3-37e6-4382-97de-0c2676bc1103&amp;name=10544-590-28%20-%200172-2407-80.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TETRACYCLINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">tetracycline hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10544-590(NDC:0172-2407)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Tetracycline Hydrochloride</strong> (TETRACYCLINE) </td>
<td class="formItem">Tetracycline Hydrochloride</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">black, yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2407</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10544-590-28</td>
<td class="formItem">28  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:10544-590-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:10544-590-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:10544-590-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA060704</td>
<td class="formItem">03/03/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Blenheim Pharmacal, Inc.
							(171434587)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Blenheim Pharmacal, Inc. (171434587)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Blenheim Pharmacal, Inc.</td>
<td class="formItem"></td>
<td class="formItem">171434587</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d10c81e5-ccfe-4977-9cb9-c7edcdda6dc8</div>
<div>Set id: d07410b3-37e6-4382-97de-0c2676bc1103</div>
<div>Version: 1</div>
<div>Effective Time: 20100420</div>
</div>
</div> <div class="DistributorName">Blenheim Pharmacal, Inc.</div></p>
</body></html>
